CLIA UPDATE Individualized Quality Control Plans (IQCP) & Regulation Updates

Judith Yost, MA, MT (ASCP)
Director
Div. of Laboratory Services





Topics for Discussion

- CLIA Data
- Status of CMS/CDC Regulations
 - PT Revisions
 - Patient Access
- IQCP Implementation
- Resources





Current Statistics-Enrollment

Total Number of Laboratories	232, 996
Total Non-Exempt	225,879
Compliance	19,354
- <u>A ccredited</u>	15,658
— Waived	153,568
- Provider Performed Microscopy	37,299
- Exempt	7117
• <i>NY</i>	3,518
• WA	3,599




CMS data base 7/2012



Current Statistics

Physician Office Laboratories by CLIA Certificate Type (Non-Exempt Only)




Source: CMS CLIA database





Current Statistics

Number of CLIA Certificate of Accreditation Laboratories by Accreditation Organization



Future of CLIA & EHR's Proposed Patient Access Rule

- Standards, practices & technology for electronic exchange of lab information are still evolving.
- CMS will revisit CLIA Interpretive Guidelines, to ensure laboratories & stakeholders have clear guidance on best practices/resources to implement Health Information Technology.
- Proposed rule for patient access to laboratory results published 9/12/11 by CMS, CDC & OCR. Comments analyzed; final responses developed.





Helpful EHR Links

- Health Information Technology
 - http://healthit.gov/portal/server.pt



- http://www.cms.gov/SurveyCertificationGenInfo/PMS
 R/list.asp#TopofPage
- OCR Posting of Security Breaches
 - http://www.hhs.gov/ocr/privacy/hipaa/administrative/br eachnotificationrule/postedbreaches.html
- FDA Safety Portal
 - https://www.safetyreporting.hhs.gov





PT Regulation Update

- Plan w/ milestones developed; no firm ETA
 - Includes: test selection, target values, grading criteria, PT programs, labs, PT referral
 - Requires a proposed rule w/ comment & final
- CLIAC recommended to proceed
 - CLIAC WG w/ SMEs from affected parties
 - 1st PT providers' meeting held; 2nd Mar. 2012
 - Method for test selection identified
- Add'l data used to determine grading criteria & target values



PT Referral Update



DO NOT SEND PT SAMPLES TO ANOTHER LABORATORY!!

- CMS Central Office continues to review all cases
- Reflex, confirmation, distributed, referral testing seem to be major causes
- Common personnel across several laboratories/health systems contribute
- Guidance--
 - For Now: Read & Follow CMS PT Brochure
 - For Future: Expect regulatory changes; legislative proposals



Background & History of CLIA Quality Control

- CLIA Law passed—1988
- Final CLIA Regulations published—1992
 - 5 basic QC requirements—mod. complexity
 - Follow manufacturer's instructions
 - All QC actions acceptable—phase in
 - All requirements apply to high complexity
- Many expert meetings convened by CDC/CMS to no avail
- Quality System Regulations pub.—2003



2003 Regulations--Inception of EQC

- New provision for alternative QC in CMS' Interpretive Guidelines (IG) in lieu of changing regulations w/ new technology, as long as "equivalent quality testing" is provided--- 42 CFR 493.1250 & 1256(d).
- Default: 2 levels external QC/day of testing
- Equivalent QC or 'EQC' developed in IG as a voluntary alternative QC--2004





EQC Follow Up

- Concerns expressed by industry, laboratories, experts, etc.
- Many laboratories adopted EQC successfully & have no quality issues; but no flexibility
- CMS reached out to CLSI to facilitate development of an scientific, objective consensus QC guideline





QC for the Future

- CLSI convened the well-attended 'QC for the Future' meeting in 2005
- Sponsored by accrediting orgs., industry, professional orgs. & gov't. agencies
- Outcome:
 - Stakeholder concern that manufacturers don't provide labs sufficient information
 - 'One-size-fits-all' QC doesn't work w/ new technology



Designing The "Right QC"

- CLSI meeting directed the development of Evaluation Protocol (EP)-23—Laboratory Quality Control Based on Risk Management
 - Chaired by James Nichols, PhD—Baystate
 Health
 - Assembled expert group
 - Published October, 2011





• CMS will incorporate key EP-23 concepts into CLIA Interpretive Guidelines (IG) as an acceptable QC policy called IQCP





- Applies to CMS-certified non-waived labs
- Covers all phases of testing process, not just
 QC
- May or may not reduce QC amt. or frequency
- IQCP is optional
- Default is regulation 493.1256(d)(3)
- Includes existing & new analytes/test systems
 & specialties, except cytology/histopathology





- Permits labs to develop an IQCP using their existing quality practices/information
 - E.g., test verification data is a start
- Considers known risks mitigated by mfgr. &
- Formalizes laboratories' risk mgt. decisions





- Can be customized based on labs' patient pop., environment, test system, personnel, test uses
- Offers flexibility to achieve QC compliance for each test
- Adaptable to future technology advancements





- Once effective, IQCP will supersede the current EQC policy
- Existing CLIA QC & quality system concepts won't change
- No regulations will change!
- CMS' outcome oriented survey won't change
- Labs must also follow mfr's. instructions
- Lab director has overall responsibility for QCP



Education & Transition Period for IQCP – Laboratories

• There'll be an education & transition period for labs before IQCP is fully effective

Info and Guidance will be provided to labs www.cms.hhs.gov/clia/

For Questions: IQCP@cms.hhs.gov





Education & Transition Period for IQCP - Laboratories

In the interim, CMS certified labs should:

- Continue to follow existing QC protocols
- Learn about EP-23 concepts & IQCP
- Plan & complete their transition accordingly
 - Phase out EQC (if using it)
 - Decide to implement default QC or IQCP





Education & Transition Period for

- CMS will notify labs of important dates:
 - Beginning of transition & education period
 - End of education & transition period
- At the end, labs must be in compliance w/ their QC choice
- Or deficiencies will be cited



Education & Transition Period for IQCP

• CMS will solicit accrediting orgs (AO) to determine their interest in IQCP

• Accredited labs should <u>continue to meet their</u> <u>accrediting org.'s QC standards</u> until they receive notice from their AO





Education & Transition Period for IQCP

 No control procedure regulatory citations will be issued prior to the end of the education & transition period unless serious test quality problems are found

• Please stay tuned.....







Where to Obtain Information

CMS/CLIA Web site:

www.cms.hhs.gov/clia/

IG, Brochures, app, IQCP Info

CMS CLIA Central Office:

410-786-3531

Judy Yost's Email:

Judith.yost@cms.hhs.gov



CP Link:

IQCP@cms.hhs.gov 25





IQCP is the Right QC!!

THE END!!
Thank You!!!
Questions????



